Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

An Open Label, Randomized, Crossover Study To Estimate The Pharmacokinetics And Evaluate The Safety Following A Single Dose Of Azithromycin 2g Extended-Release Powder For Oral Suspension With A 3-Day Dosing Regimen Of Azithromycin 500mg Tablet In Chinese Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: azithromycin (Zithromax)

First Posted Date: 2009-04-13

Last Posted Date: 2010-06-14

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT00879983

Locations: 🇨🇳
Pfizer Investigational Site, Shanghai, China

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Phase 1

Completed

Conditions: Meningitis, Meningococcal

Interventions: Biological: rLP2086 vaccine or control

First Posted Date: 2009-04-13

Last Posted Date: 2015-08-06

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT00879814

Locations: 🇺🇸
Miami Research Associates, Inc., South Miami, Florida, United States

Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Malignancy
Neoplasms
Advanced Solid Tumors
Carcinoma
Cancer

Interventions: Biological: CVX-060

First Posted Date: 2009-04-10

Last Posted Date: 2015-01-26

Lead Sponsor: Pfizer

Target Recruit Count: 34

Registration Number: NCT00879684

Locations: 🇺🇸
Premiere Oncology, A Medical Corporation, Santa Monica,, California, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Scottsdale Medical Imaging, Ltd., Scottsdale, Arizona, United States

and more 1 locations

A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors
Neoplasms
Carcinoma
Cancer
Malignancy

Interventions: Biological: CVX-045

First Posted Date: 2009-04-10

Last Posted Date: 2010-12-13

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT00879554

Locations: 🇺🇸
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States

Toviaz Post Marketing Surveillance Study

Completed

Conditions: Overactive Bladder

Interventions: Drug: Toviaz treatment

First Posted Date: 2009-04-10

Last Posted Date: 2015-10-21

Lead Sponsor: Pfizer

Target Recruit Count: 3000

Registration Number: NCT00879398

Locations: 🇰🇷
Hankook General Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
🇰🇷
Lee Urology Clinic, Namyangju-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Moa gynecology, Nonsan-si, Chungcheongnam-do, Korea, Republic of

and more 72 locations

A Trial In Patients With Advanced Cancer And Leukemia

Phase 1

Completed

Conditions: Neoplasms by Histologic Type

Interventions: Drug: PF-03084014

First Posted Date: 2009-04-08

Last Posted Date: 2019-11-12

Lead Sponsor: Pfizer

Target Recruit Count: 72

Registration Number: NCT00878189

Locations: 🇺🇸
Massachusetts General Hospital Clinical Laboratory, Boston, Massachusetts, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇮🇹
DIPRTMNT CLIN Scienze RADIOL e Istocitopatologiche, Bologna, Italy

and more 7 locations

A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: PF-03526299
Drug: Placebo
Drug: Fluticasone propionate

First Posted Date: 2009-04-07

Last Posted Date: 2010-09-28

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT00877539

Locations: 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom

Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration

Phase 1

Completed

Conditions: Age-Related Maculopathy
Eye Diseases
Age-Related Maculopathies
Retinal Degeneration
Macular Degeneration

Interventions: Biological: RN6G
Biological: Placebo

First Posted Date: 2009-04-07

Last Posted Date: 2015-03-31

Lead Sponsor: Pfizer

Target Recruit Count: 57

Registration Number: NCT00877032

Locations: 🇺🇸
Dedicated Phase 1, Phoenix, Arizona, United States
🇺🇸
Retinal Consultants of AZ, Phoenix, Arizona, United States
🇺🇸
Insight Diagnostic Imaging Center, Phoenix, Arizona, United States

and more 16 locations

A Study of Tanezumab in Adults With Chronic Low Back Pain

Phase 2

Completed

Conditions: Low Back Pain

Interventions: Biological: Tanezumab 20 mg IV
Biological: Tanezumab 10 mg IV
Biological: Tanezumab 5 mg IV
Biological: Placebo for tanezumab
Drug: Placebo for naproxen
Drug: Naproxen

First Posted Date: 2009-04-06

Last Posted Date: 2021-07-07

Lead Sponsor: Pfizer

Target Recruit Count: 1359

Registration Number: NCT00876187

Locations: 🇺🇸
Comprehensive Clinical Research, Berlin, New Jersey, United States
🇺🇸
Advances In Health, Inc., Houston, Texas, United States
🇺🇸
Clinical Research Consortium, Las Vegas, Nevada, United States

and more 126 locations

A Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: PF-00868554 or Placebo

First Posted Date: 2009-04-03

Last Posted Date: 2009-10-22

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT00875628

Locations: 🇺🇸
Pfizer Investigational Site, Glendale, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy